4DMedical Extends Imaging Technology into Public Hospitals and National Screening Network

4DMedical (ASX: 4DX) has secured three significant agreements to expand the reach of its lung health imaging technology.

In Australia, 4DMedical has locked in a multi-year deal with Spectrum Medical Imaging to support the National Lung Cancer Screening Program.

The company will also launch a Brazilian lung screening program with a leading pharmaceutical partner, while Royal Melbourne Hospital will pilot its full software portfolio.

Brazilian Partnership Targets Early Detection

In Brazil, 4DMedical has begun rolling out a lung health screening program in collaboration with a global pharmaceutical company.

The first site is Hospital Madre Teresa in Belo Horizonte, with an initial phase covering eight hospitals.

The program will assess up to 10,000 scans through to August 2026, with a focus on lung cancer detection and identifying incidental conditions such as coronary artery calcification and chronic obstructive pulmonary disease.

The company said the initiative could ultimately provide national coverage across Brazil, offering access to advanced respiratory imaging for millions of people.

Royal Melbourne Hospital to Deploy Full Portfolio

Royal Melbourne Hospital has signed on as the first Australian public hospital and academic medical centre to pilot the complete 4DMedical suite.

The agreement runs until 31 December 2025 and covers all advanced lung ventilation and imaging tools, including the CT Lung Ventilation Analysis Software (CT LVAS), XV LVAS, Lung Density Analysis (LDAi), Lung Texture Analysis, and low-dose CT nodule detection.

Chief executive officer Andreas Fouras said he was excited to see the hospital adopt the full portfolio, extending 4DMedical’s technology into frontline clinical practice.

“Since announcing FDA clearance for CT:VQ, we’ve experienced a very real change in our interactions with healthcare providers—I look forward to providing shareholders with further updates as they become available,” he said.

Spectrum Agreement Strengthens Screening Role

4DMedical has also executed a multi-year agreement with Spectrum Medical Imaging in New South Wales to support the National Lung Cancer Screening Program.

The deal, which runs until 30 June 2027, expands Spectrum’s offering beyond CT LVAS to include low-dose CT nodule detection and additional structural imaging reports.

Spectrum co-founder Dr Glen Schlaphoff said the partnership would “redefine how lung diseases are detected, understood, and treated” by enabling clinicians to extract functional data from standard CT scans.

Mr Fouras added that the agreements demonstrate the company’s growing international reputation, highlighting Brazil as “a real opportunity to expand our reach to millions in South America”.